Contrasting Retrophin (RTRX) & The Competition

Retrophin (NASDAQ: RTRX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Retrophin to related companies based on the strength of its risk, analyst recommendations, institutional ownership, valuation, profitability, dividends and earnings.


This table compares Retrophin and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Retrophin -33.79% -10.13% -5.94%
Retrophin Competitors -5,361.25% -213.57% -39.75%

Analyst Ratings

This is a breakdown of current recommendations and price targets for Retrophin and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Retrophin 0 0 3 0 3.00
Retrophin Competitors 864 3216 11668 232 2.71

Retrophin currently has a consensus target price of $36.00, indicating a potential upside of 63.34%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.26%. Given Retrophin’s stronger consensus rating and higher possible upside, analysts clearly believe Retrophin is more favorable than its peers.

Institutional & Insider Ownership

50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 2.9% of Retrophin shares are held by insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Retrophin and its peers top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Retrophin $133.59 million -$47.90 million -14.60
Retrophin Competitors $284.28 million $33.78 million 82.49

Retrophin’s peers have higher revenue and earnings than Retrophin. Retrophin is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Retrophin has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Retrophin’s peers have a beta of 0.36, indicating that their average share price is 64% less volatile than the S&P 500.


Retrophin beats its peers on 7 of the 12 factors compared.

About Retrophin

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with's FREE daily email newsletter.

Leave a Reply